Список проголосовавших за комментарий " Ligand Pharma discloses that on March 1, it entered into a worldwide platform license agreement with bluebird bio (BLUE) (103.65)Under the license, bluebird will be able to use the OmniRat, OmniMouse and OmniFlic platforms to discover fully human mono- and bispecific antibodies and antibody fragments. The co is eligible to receive annual platform access payments, development milestone payments and royalties for each product incorporating an OmniAb antibody. Bluebird will be responsible for all costs related to the programs. The co previously disclosed rights to a single-antibody partnership had been licensed to bluebird but this agreement gives bluebird full access to the OmniAb platform."